(Q40892619)

24 September 2017

1 reference

title

Molecular mechanisms and future uses of antiestrogens (English)

1 reference

24 September 2017

Jordan VC

1

1 reference

PubMed ID

9220447

24 September 2017

Gradishar WJ

series ordinal

2

1 reference

24 September 2017

1 June 1997

1 reference

24 September 2017

81

1 reference

Molecular Aspects of Medicine

inferred from page(s)

published in

1 reference

24 September 2017

18

1 reference

24 September 2017

3

1 reference

24 September 2017

167-247

1 reference

Japanese early phase II study of droloxifene in the treatment of advanced breast cancer. Preliminary dose-finding study

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Pharmacokinetics of toremifene

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Gynecologic effects of tamoxifen and the association with endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Preparation and Identification of cis and trans Isomers of a Substituted Triarylethylene

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

European early phase II dose-finding study of droloxifene in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

High-performance liquid chromatographic analysis of tamoxifen, toremifene and their major human metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Antagonism of estrogen action with a new benzothiophene derived antiestrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Sex hormones and renal neoplasia.Inhibition of tumor of hamster kidney by an estrogen antagonist, an agent of possible therapeutic value in man

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Estrogen-Like Action of Tamoxifen on Vaginal Epithelium in Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Novel steroidal pure antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Phase II Evaluation of Lyl56758 in Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Clinical significance of tamoxifen withdrawal response

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

The effect of tamoxifen and two of its non-isomerizable fixed-ring analogs on multistage rat hepatocarcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Antiestrogenic properties of raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effects of a non-steroidal pure antioestrogen, ZM 189,154, on oestrogen target organs of the rat including bones

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Pharmacologic and biologic properties of droloxifene, a new antiestrogen.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Stereochemistry of geometric isomers of clomiphene: A Correction of the Literature and a Reexamination of Structure‐Activity Relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effects of MER-29 on the intermediary metabolism of cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

The pharmacology and clinical uses of tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Biosynthesis of skin sterols. II. Reduction of delta 24-unsaturated sterols of rat skin

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Induction of ovulation with MRL/41. Preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Induction of ovulation

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Sequence and expression of human estrogen receptor complementary DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

EFFECTS OF A DIHYDRONAPHTHALENE DERIVATIVE (U-11100A) ON PREGNANCY IN THE RAT

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effects of the antiestrogen toremifene on growth of the human mammary carcinoma cell line MCF-7.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Pharmacokinetics of droloxifene and its metabolites in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Droloxifene--a new anti-estrogen. A phase II study in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Influence of Synthetic Oestrogens on Advanced Malignant Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Phase I study of toremifene in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Contrasting Endocrine Activities of cis and trans Isomers in a Series of Substituted Triphenylethylenes

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

A new derivative of triphenylethylene: effect on implantation and mode of action in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Preclinical data for Droloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Clinical trial of clomiphene in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effect of toremifene in breast cancer patients. Preliminary communication

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Response after withdrawal of tamoxifen and progestogens in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Cell proliferation in dimethylbenz(A)anthracene(DMBA)-induced rat mammary carcinoma treated with antiestrogen toremifene

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

A new triphenylethylene derivative, TAT-59; hormone receptors; insulin-like growth factor 1; and growth suppression of hormone-dependent MCF-7 tumors in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Use of tamoxifen for breast cancer: twenty-eight years later

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methanone, methanesulfonic acid salt

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Tamoxifen and tumorigenicity: a predictable concern

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? A personal perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Should clinicians be concerned about the carcinogenic potential of tamoxifen?

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Structural derivatives of tamoxifen and oestradiol 3-methyl ether as potential alkylating antioestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effects of anti-estrogens on bone in castrated and intact female rats

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Review of the pharmacological properties of toremifene

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Biochemical and pharmacological effects of toremifene metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

The Estrogenic and Antiestrogenic Activities of Droloxifene in Human Breast Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Cataract Formation After Triparanol Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effect of toremifene on clinical chemistry, hematology and hormone levels at different doses in healthy postmenopausal volunteers: phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Induction of Transforming Growth Factor β by the Antiestrogens Droloxifene, Tamoxifen, and Toremifene in MCF-7 Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Cataracts in Patients Treated with Triparanol

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Trioxifene mesylate in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Nafoxidine--an antiestrogen for the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

No loss of estrogenic or anti-estrogenic activity after demethylation of droloxifene (3-OH-tamoxifen)

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effect of toremifene on estrogen primed vaginal mucosa in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

The human oestrogen receptor functions in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Molecular mechanisms of resistance to tamoxifen therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Estrogen deprivation in breast cancer. Clinical, experimental, and biological aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Substituted Aminoalkoxytriarylhaloethylenes

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB)

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Droloxifene, a new antiestrogen: its role in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Duration of Action of Natural and Synthetic Œstrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Activity of the antioestrogen trioxifene against N-Nitrosomethylurea-induced rat mammary carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Antiestrogenic effects of LY 117018 in MCF-7 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

EFFECTS OF TRIPARANOL (MER-29) ON CHOLESTEROL BIOSYNTHESIS AND ON BLOOD STEROL LEVELS IN MAN

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Influence of toremifene on the endocrine regulation in breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Interaction of DP-TAT-59, an active metabolite of new triphenylethylene-derivative (TAT-59), with estrogen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Possible mechanisms in the emergence of tamoxifen-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Targeted anti-estrogens to treat and prevent diseases in women

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Effects of tamoxifen on spinal bone density in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Phase II experience with toremifene in the treatment of ER-positive breast cancer of postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

RU 58,668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Risk of endometrial cancer after tamoxifen treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

1-(aminoalkyl)-2-phenylindoles as novel pure estrogen antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Steroidal pure antioestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Novel antioestrogens without partial agonist activity

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Synthetic oestrogens in mammary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

High-performance liquid chromatographic method for the determination of toremifene and its major human metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Investigations of droloxifene and other hormone manipulations on N-nitrosomethylurea-induced rat mammary tumours. 1. Influence on tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Tamoxifen inhibits lipid peroxidation in cardiac microsomes. Comparison with liver microsomes and potential relevance to the cardiovascular benefits associated with cancer prevention and treatment by tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen?

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Inhibition of growth-factor-activated proliferation by anti-estrogens and effects on early gene expression of MCF-7 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2896%2900015-5

7 January 2021

10.1016/S0098-2997(96)00015-5

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9220447